Jessica N. Everett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jessica N. Everett has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Diane M. Simeone
Moores Cancer Center, UC San Diego Health, San Diego, USA
18 shared publications - Sonia S. Kupfer
Affiliations Section of Gastroenterology, Hepatology & Nutrition, Department of Medicine, University of Chicago, Chicago, Illinois, United States of America, Section of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, Illinois, United States of America
17 shared publications Aaron Grossberg
16 shared publications- Aimee L. Lucas
Division of Gastroenterology and Hepatology, Mount Sinai Morningside and Mount Sinai West, Icahn School of Medicine at Mount Sinai, New York, NY
16 shared publications Andrew Lowy
16 shared publications- Bryson William Katona
Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
16 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 4: Consent and biosample collection rates amongst HRIs stratified by high-risk subgroup
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 4: Consent and biosample collection rates amongst HRIs stratified by high-risk subgroup
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 3: Consent and biosample collection rates amongst HRIs stratified by sex
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 3: Consent and biosample collection rates amongst HRIs stratified by sex
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 1: Comparison of rates of pathogenic variants and cancer history by sex
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 1: Comparison of rates of pathogenic variants and cancer history by sex
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 5: Consent and biosample collection rates amongst HRIs stratified by age
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 5: Consent and biosample collection rates amongst HRIs stratified by age
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 2: Comparison of baseline characteristics of HRIs by site location
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 2: Comparison of baseline characteristics of HRIs by site location
- Open Access
The role of family history in predicting germline pathogenic variant carriers who develop pancreatic cancer: Results of a multicenter collaboration
Background: Pancreatic ductal adenocarcinoma (PDAC) surveillance is recommended for some individuals with a pathogenic or likely pathogenic variant (PV/LPV) in a PDAC susceptibility gene; the recommendation is often dependent on family history of PDAC. This study aimed to describe PDAC family history in individuals with PDAC who underwent genetic testing to determine the appropriateness of including a family history requirement in these recommendations.Methods: Individuals with PDAC with a germline heterozygous PV/LPV in ATM, BRCA1, BRCA2, EPCAM, MLH1, MSH2, MSH6, PALB2, or PMS2 (PV/LPV carriers) were assessed for family history of PDAC in first‐degree relatives (FDRs) or second‐degree relatives (SDRs) from nine institutions. A control group of individuals with PDAC without a germline PV/LPV was also assessed.Results: The study included 196 PV/LPV carriers and 1184 controls. In the PV/LPV carriers, 25.5% had an affected FDR and/or SDR compared to 16.9% in the control group (p = .004). PV/LPV carriers were more likely to have an affected FDR compared to the controls (p = .003) but there was no statistical difference when assessing only affected SDRs (p = .344).Conclusions: Most PV/LPV carriers who developed PDAC did not have a close family history of PDAC and would not have met most current professional societies’ recommendations for consideration of PDAC surveillance before diagnosis. However, PV/LPV carriers were significantly more likely to have a family history of PDAC, particularly an affected FDR. These findings support family history as a risk modifier in PV/LPV carriers, and highlight the need to identify other risk factors.
Open AccessThe role of family history in predicting germline pathogenic variant carriers who develop pancreatic cancer: Results of a multicenter collaboration
Background: Pancreatic ductal adenocarcinoma (PDAC) surveillance is recommended for some individuals with a pathogenic or likely pathogenic variant (PV/LPV) in a PDAC susceptibility gene; the recommendation is often dependent on family history of PDAC. This study aimed to describe PDAC family history in individuals with PDAC who underwent genetic testing to determine the appropriateness of including a family history requirement in these recommendations.Methods: Individuals with PDAC with a germline heterozygous PV/LPV in ATM, BRCA1, BRCA2, EPCAM, MLH1, MSH2, MSH6, PALB2, or PMS2 (PV/LPV carriers) were assessed for family history of PDAC in first‐degree relatives (FDRs) or second‐degree relatives (SDRs) from nine institutions. A control group of individuals with PDAC without a germline PV/LPV was also assessed.Results: The study included 196 PV/LPV carriers and 1184 controls. In the PV/LPV carriers, 25.5% had an affected FDR and/or SDR compared to 16.9% in the control group (p = .004). PV/LPV carriers were more likely to have an affected FDR compared to the controls (p = .003) but there was no statistical difference when assessing only affected SDRs (p = .344).Conclusions: Most PV/LPV carriers who developed PDAC did not have a close family history of PDAC and would not have met most current professional societies’ recommendations for consideration of PDAC surveillance before diagnosis. However, PV/LPV carriers were significantly more likely to have a family history of PDAC, particularly an affected FDR. These findings support family history as a risk modifier in PV/LPV carriers, and highlight the need to identify other risk factors.
- Open Access
- 5 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 4: Consent and biosample collection rates amongst HRIs stratified by high-risk subgroup
- 5 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 4: Consent and biosample collection rates amongst HRIs stratified by high-risk subgroup
- Open Access
- 5 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 3: Consent and biosample collection rates amongst HRIs stratified by sex
- 5 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 3: Consent and biosample collection rates amongst HRIs stratified by sex
- Open Access
- 5 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 3: Consent and biosample collection rates amongst HRIs stratified by sex
- 5 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 3: Consent and biosample collection rates amongst HRIs stratified by sex
- Open Access
- 5 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 2: Comparison of baseline characteristics of HRIs by site location
- 5 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 2: Comparison of baseline characteristics of HRIs by site location